[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354119-105":59,"doc-detail-354119-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","next-generation-anticancer-peptides-engineering-nanotheranostics-and-clinical-translation","Next-Generation Anticancer Peptides - Engineering, Nanotheranostics and Clinical Translation","","Anticancer peptides (ACPs) are presented as next-generation therapeutics that combine molecular precision with multifunctional tunability. Their inherent selectivity is driven by preferential malignant-cell membrane interactions, immunomodulation, and interference with oncogenic signalling. The review details peptide-engineering strategies that improve stability, potency, and pharmacokinetics, alongside nanotechnology-enabled delivery and multimodal theranostic integration. It also addresses remaining translational hurdles spanning stability, immunogenicity, manufacturing scalability, and regulatory alignment.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/next-generation-anticancer-peptides-engineering-nanotheranostics-and-clinical-translation/354119/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/next-generation-anticancer-peptides-engineering-nanotheranostics-and-clinical-translation/354119.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What makes anticancer peptides (ACPs) different from conventional small-molecule chemotherapy?","Question",{"text":113,"@type":114},"ACPs can preferentially target malignant cells through membrane interactions, immunomodulation, and disruption of oncogenic signalling pathways, offering selectivity beyond many conventional agents.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which peptide-engineering approaches are highlighted to improve ACP performance?",{"text":118,"@type":114},"The review covers sequence optimization and chemical/structural modifications such as non-natural amino acids, cyclization, stapling, PEGylation, and refinement guided by structure–activity relationships.",{"name":120,"@type":111,"acceptedAnswer":121},"How does nanotechnology enhance the clinical translation of ACPs?",{"text":122,"@type":114},"Nanocarriers support controlled release, cancer-cell specific targeting, and multimodal theranostic integration, using platforms such as lipid and polymeric systems, dendrimers, mesoporous silica nanoparticles, and stimuli-responsive designs.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354119,1790154861,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Nanotheranostics 2026, Vol. 10 115  \nIvyspring  \nInternational Publisher  \nNanotheranostics  \n2026; 10: 115-141. doi: 10.7150/ntno.133576  \nReview  \nNext-Generation Anticancer Peptides: Engineering, Nanotheranostics and Clinical Translation  \nAbhishesh Kumar Mehata1􀀍, Shinsuke Fukui1, Yoshihiro Izumiya1,2,3  \n1. Department of Dermatology, School of Medicine, University of California, Davis (UC Davis), 3301 C-street, Sacramento, CA 95816, USA.  \n2. Department of Biochemistry and Molecular Medicine, School of Medicine, UC Davis, 4645 2nd Avenue, Sacramento, CA 95817, USA.  \n3. UC Davis Comprehensive Cancer Center, 2279 45th St, Sacramento, CA 95817, USA.  \n􀀍 Corresponding author: Dr. Abhishesh Kumar Mehata, Department of Dermatology, School of Medicine, University of California, Davis (UC Davis), 3301 C-street, Sacramento, CA 95816, USA. E-mail: [akmehata@health.ucdavis.edu](akmehata@health.ucdavis.edu).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2026.02.25; Accepted: 2026.04.06; Published: 2026.04.16  \nAbstract  \nAnticancer peptides (ACPs) have emerged as a transformative class of next-generation therapeutics that bridge molecular precision with multifunctional tunability. Unlike many conventional small molecule chemotherapeutics, ACPs offer intrinsic selectivity toward malignant cells through preferential membrane targeting, immunomodulation, and disruption of oncogenic signalling pathways. Advances in peptide engineering, including sequence optimization, incorporation of non-natural amino acids, cyclization, stapling, PEGylation, and structure–activity relationship–guided refinement, have substantially improved their stability, potency, and pharmacokinetic performance. Parallel progress in nanotechnology has further expanded the translational potential of ACPs by enabling controlled release, cancer cell specific targeting, and multimodal theranostic integration. Lipid nanoparticles, solid lipid nanoparticles, polymeric systems, dendrimers, mesoporous silica nanoparticles, and stimuli-responsive platforms now provide multiple and combinatorial strategies to overcome biological barriers, enhance intracellular delivery, and minimize systemic toxicity. Emerging concepts such as enzyme-activated nanocarriers, ligand-directed precision delivery, and light-or pH-responsive systems are redefining and energizing the spatial and temporal control of peptide therapeutics research fields. Despite encouraging preclinical and early clinical progress, including FDA-approved peptide-based agents and peptide receptor radionuclide therapies, challenges related to stability, immunogenicity, manufacturing scalability, and regulatory harmonization remain significant. This review highlights current advances in ACP discovery, molecular engineering, and nanotheranostic integration, and outlines a roadmap for advancing peptide-based precision oncology. Collectively, next-generation ACP platforms hold promise to reshape cancer therapy by integrating targeted cytotoxicity, immune activation, and real-time imaging within a single modular framework.  \nKeywords: anticancer peptide, targeted cancer therapy, drug delivery, theranostics, clinical translation  \n1. Introduction  \nCancer remains a leading global health challenge in 2026, with over 2.1 million new cases projected tobe diagnosed in the USA, and over ∼626,000 deaths expected, unfortunately [1, 2] . Conventional chemotherapy has limitations in treating cancer, asthe tumor can often develop resistance to chemotherapy, leading to reduced therapeutic efficacy and increasing adverse effects after therapy [3] . Many small peptides have been discovered to  \nhave anti-cancer activity in a variety of species, along with the develop","cbCaibuKrZC74kpl","https://ap.wps.com/l/cbCaibuKrZC74kpl","pdf",11900499,27,"English","# Introduction\n# Anticancer peptides: engineering and activity\n# Nanotheranostics and theranostic delivery systems\n# Translational progress and clinical outlook\n# Challenges and future roadmap","[{\"question\":\"What makes anticancer peptides (ACPs) different from conventional small-molecule chemotherapy?\",\"answer\":\"ACPs can preferentially target malignant cells through membrane interactions, immunomodulation, and disruption of oncogenic signalling pathways, offering selectivity beyond many conventional agents.\"},{\"question\":\"Which peptide-engineering approaches are highlighted to improve ACP performance?\",\"answer\":\"The review covers sequence optimization and chemical/structural modifications such as non-natural amino acids, cyclization, stapling, PEGylation, and refinement guided by structure–activity relationships.\"},{\"question\":\"How does nanotechnology enhance the clinical translation of ACPs?\",\"answer\":\"Nanocarriers support controlled release, cancer-cell specific targeting, and multimodal theranostic integration, using platforms such as lipid and polymeric systems, dendrimers, mesoporous silica nanoparticles, and stimuli-responsive designs.\"}]","Next-Generation Anticancer Peptides - Engineering, Nanotheranostics and Clinical Translation | PDF",1790109102,68,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8fcecc493c9e39152f184d9813da433d.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dd1fe8f05096808dc065d3bf6d1d886.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2e24b138cc23fdfd17a49cf1cc3954f.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09830aa14cc5bc0fa0d91c7e8d3d1b25.webp",980,1268]